Moderna cuts 2025 sales view on slow start to RSV shot, weak COVID vaccine demand
(Reuters) - Moderna (MRNA) cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow launch of ...
Read moreDetailsTag: COVID vaccine
Novavax cuts 2024 revenue forecast again on lower COVID vaccine sales
By Patrick Wingrove (Reuters) -Novavax (NVAX) cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ...
Read moreDetails
